The new findings are the first to describe distributions and perturbations of low-density granulocyte and normal-density ...

Saeed Sadeghi, MD, discusses the findings on transfusion independence achieved with treatment for patients with low-risk ...

The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

Geron Corp's Rytelo launch & robust pipeline offer a compelling investment opportunity, despite stock challenges. Click here ...

Palak Dave discusses the potential role of artificial intelligence in improving the accuracy of myelodysplastic syndromes diagnosis.

VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today an ...

In August 2024, the U.S. Food and Drug Administration (FDA) granted bexmarilimab fast track designation, acknowledging its potential to address unmet medical needs in MDS treatment. The interim ...

outperforming classical approaches for patients with myelodysplastic syndromes (MDS), according to a study published online in the April issue of Computer Methods and Programs in Biomedicine.